Objective: The objective of this study was to evaluate the association of urine clusterin/apolipoprotein J (Apo J) with the development and/or progression of diabetic kidney disease (DKD) in type 2 diabetes. Results: Baseline clusterin levels in urine were significantly increased in type 2 diabetic subjects compared with those of nondiabetic subjects. The levels of urine clusterin had a significant correlation with urine tubular damage markers. A positive correlation between the annual rate of decline in eGFR and urine clusterin after adjusting for clinical confounding factors was detected. Multivariate analysis further indicated that urine clusterin correlated with the development of CKD stage 3 or greater and persistence/progression of albuminuria. In type 2 diabetic subjects with albuminuria, urine clusterin remained associated with the annual decline rate in eGFR and the progression of CKD stage.
| INTRODUCTION
The prevalence of diabetes is increasing worldwide, and its complication of diabetic kidney disease (DKD) is a major global healthcare and socio-economic burden, with serious effects for individual patients. [1] [2] [3] DKD is clinically characterized by persistent albuminuria and a progressive decline in glomerular filtration rate (GFR) and is the leading cause of end-stage renal disease (ESRD). 2 To improve the lives of people with DKD, identification of a new marker that can predict the development and progression of DKD at an early stage is urgently needed.
It is clear that the presence of albuminuria is considered to be an early sensitive marker of DKD. 2 However, significant glomerular damage has already occurred when albuminuria is present. 4 In addition,
there is a limited value in the use of albuminuria because not everyone with DKD and reduced GFR has increased albuminuria and because the methodology for measuring albuminuria is not well standardized due to individual variability. 2 Thus, the issue of whether albuminuria can be used as an early marker for DKD has been an outstanding subject in the field.
Over the past few years, significant advances have been made in identifying new diagnostic tools and noninvasive biomarkers for DKD, especially using urine samples. 5, 6 Urine biomarkers in DKD patients can be categorized based on the pathogenic features of glomerular or tubular dysfunction. 6 Although glomerular dysfunction has been thought to be a key factor for the development and/or progression of DKD, recent studies demonstrate that involvement of renal tubular damage is crucial in the pathogenesis of DKD. 7, 8 In clinical practice, the importance of tubular damage has been underestimated because of the limitation of sensitive tests for this in human subjects.
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Clusterin, also known as apolipoprotein J (Apo J), is a glycoprotein expressed ubiquitously in various metabolic tissues and body fluids. 9 Clusterin is shown to be involved in the regulation of remodelling, lipid transport, complement inhibition and apoptosis. 10 Clusterin also plays an important role in cardiovascular-related diseases, including dyslipidaemia, atherosclerosis, obesity and type 2 diabetes, [11] [12] [13] all of which are pathogenic features of insulin resistance. In response to acute renal injury, including ischaemia/reperfusion injury, toxininduced kidney injury and unilateral ureteral obstruction, clusterin is rapidly induced in the kidney and urine. 14 Interestingly, a higher level of clusterin is found in dedifferentiated tubular cells of the kidney.
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Thus, it is important to know that urine clusterin could be used as a tubular damage marker and is involved in development and/or progression of DKD.
In this study, we evaluated the clinical implications of urine clusterin on the early development and/or progression of DKD in human subjects with type 2 diabetes. We also determined whether urine clusterin correlates with urine tubular makers and the annual rate of decline in eGFR in type 2 diabetic patients. Finally, we further evaluated whether urine clusterin can predict the persistence/progression of chronic kidney disease (CKD) stage and the persistence or progression of albuminuria. As a part of the DKDS, patients' follow-up is still ongoing.
| SUBJECTS AND METHODS

| Study population and design
Appropriate diabetes management, according to well-known standard For the analysis of this study, the patients were followed up until March 2016. 20 mg/L and <0.48% for total proteinuria and 4 mg/L and <7.4%
| Metabolic parameter measurements and definitions
for albuminuria. The urine nonalbumin protein-to-creatinine ratio (NAPCR) was calculated using total proteinuria and albuminuria:
NAPCR=protein-to-creatinine ratio (PCR)−albumin-to-creatinine ratio (ACR). and 6.9%-7.5%; for KIM-1, 3.9%-4.4% and 6.0%-7.8%; for NGAL, 3.1%-4.4% and 5.6%-7.9%; for LFABP, 9.6%-11.9% and 3.5%-7.9%.
The data for urine markers were expressed as ratios of urine marker to urine creatinine (urine marker/Cr) to assess the hydration state and renal function of the patients.
| Statistical analysis
Statistical analyses were performed using SPSS version 18.0 for windows (SPSS, Inc., Chicago, IL, USA). Type 2 diabetic patients were divided into quartile groups according to their baseline urine Clusterin/ 
| RESULTS
| Clinical and metabolic characteristic of study subjects
| Association of the annual rate of decline in eGFR with urine clusterin levels
The median follow-up duration was 3.0 years (range, 1.0-5.9 years).
In all diabetic patients, the median annual rate of decline in eGFR was Figure 1A and Table 4 ).
After adjusting for age, sex and clinical confounding factors including HbA1c, SBP, HDL cholesterol and duration of diabetes, urine clusterin level significantly associated with annual rate of decline in eGFR (standard β=.283, P=.004, Table 4 Table 5 and Figure 1D ).
| Association of development of CKD 3 or greater and persistence/progression of albuminuria with urine clusterin levels
Finally, urine clusterin was associated with albuminuria persistence/ progression (Q3 vs Q1: HR, 9.94; 95% CI=2.02-48.87; P=.005). When we analysed clusterin levels of patients in the albuminuria group, there was a marked difference in the cumulative incidence of CKD 3 or greater in patients according to urine clusterin quartile groups (P=.021, Figure 1E ). In addition, the highest quartile group of urine clusterin (Q4) showed a higher cumulative incidence of CKD stage 3 or greater than that of the lowest quartile group (Q4 vs Q1: HR, 4.85, 95% CI=1.08-21.74, P=.039).
| DISCUSSION
The is related to a decrease in renal concentrating ability and GFR levels. suggesting that urine clusterin is involved in the renal injury of CKD.
Given that clusterin expression was greatly upregulated in the tubular epithelium of dilated, convoluted proximal tubules, 21 it is conceivable that urine clusterin is a decisive indicator of tubular abnormalities. Together, these observations raised the possibility that clusterin functions as a potential marker during renal injury in both acute and chronic kidney diseases.
It is likely that increased levels of clusterin in urine are more closely associated with tubular damage than with glomerular damage. For example, de novo clusterin synthesis was elevated in the renal tubular epithelium after renal injury and then excreted in the urine. 22 In addition, induction of clusterin primarily occurred in the tubular epithelial cell but not in the glomerulus of the kidneys of the nephrotic animal model and ultimately precedes the development of tubular disease.
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Moreover, urine clusterin showed a better diagnostic performance compared with serum blood urea nitrogen (BUN) and creatinine for detecting proximal tubular injury, whereas urine total protein, cystatin C and β2-microglobulin displayed a better diagnostic performance for detecting glomerular injury. 23 These observations, combined with our findings that urine clusterin correlates with tubular damage markers in type 2 diabetic subjects, suggest that elevation of urine clusterin could be a tubular damage marker in DKD. Among two models for kidney injury leading to CKD, the "fibrosis hypothesis" suggests that a variety of initial kidney insults result in tubular injury, eliciting further inflammation and damage to the tubulointerstitium that proceeds to CKD. In this study, the finding that clusterin correlated with stage 3 CKD or progression of albuminuria might reinforce that at this stage, tubular damage may be more evident.
We propose the hypothesis that upregulation of urine clusterin along with albuminuria may reflect proteinuria-induced renal injury/ apoptosis. In support of this, an in vitro study demonstrates that treatment of cultured mouse proximal tubule cells with albumin leads to increased clusterin levels in the media, which in turn inhibits the NF-kB signalling pathway. As a result, albumin-stimulated apoptosis in tubule cells is increased. 25 Although albuminuria has been thought to be a sensitive marker for DKD, there is a concern about the pathogenic nature of DKD's progression. Interestingly, diabetic patients who have albuminuria sometimes show spontaneous remission to normal albumin levels, while others progress kidney failure during the course of a longterm follow-up. 25, 26 Thus, it appears that the use of only albuminuria as a predictor of progression of the disease could provide incorrect information in DKD patients. Combined with information from urine clusterin, however, the progression of DKD can correctly be predicted in diabetic patients.
It has been reported that glomerular clusterin is variably expressed in human membranous nephritis, a major cause of nephrotic syndrome; it has also emerged as a factor influencing proteinuria and was associated with a reduction in proteinuria after a follow-up of 1.5 years. 27, 28 In this regard, mice lacking clusterin developed a progressive glomerulopathy characterized by the deposition of immune complexes in the mesangium. 29 These results support the notion that clusterin may have a protective role for CKD and can modify immune complex metabolism and disposal. However, it is uncertain whether this glomerular clusterin is correlated with the emergence and increase in urine clusterin in the development and/or progression of DKD.
Evidence revealed that RAS may affect renal clusterin expression during the renal injury. [30] [31] [32] Clusterin attenuates angiotensin II-induced renal fibrosis through the inhibition of NF-κB signalling and the downregulation of angiotensin II type I receptor (AT1R) signalling, indicating that there is a link between clusterin and angiotensin II signalling in the context of renal disease. 33 A study with the nephrectomized rat model demonstrated that nephrectomy caused a progressive increase in clusterin mRNA levels in the remnant kidney and that an angiotensinconverting enzyme (ACE) inhibitor prevented the injury-induced increase in clusterin mRNA and proteinuria. 31 Collectively, these data suggest that the induction of clusterin is sensitive to renal injury, along with proteinuria, and is modulated by the renin-angiotensin system. In this respect, we exclude the possibility that urine clusterin levels in our patients are reflected in the renin-angiotensin system as the patients taking RAS inhibitors had a sufficient washout period for these drugs before the study.
The potential limitations of the current study come from the fact that urine clusterin is also increased by acute renal injury such as ischaemia/reperfusion injury, toxicant-induced kidney injury and unilateral ureteral obstruction, 14, 23 all of which are often found in diabetic patients. Thus, if urine clusterin is applied as a biomarker of renal injury in the clinical setting, it is difficult to discriminate between acute renal injury and chronic kidney disease. Given that increased levels of urine clusterin after acute injury can decline, 34 it would be important to know the kinetics of the short-term changes in the context of acute damage, which could provide an important clue to overcome this limitation. Even though we excluded patients with several acute illnesses which might affect the natural course of DKD at baseline and during the follow-up period, it is unlikely that our subjects could distinguish between AKI and DKD.
The cohort size is relatively small, and the follow-up period was short. As the development and progression of DKD have a variable course and require a longer time frame, a large cohort study will be needed to further confirm the concept of this study. As the MDRD equation is less accurate, especially in a cohort of patients, at levels above 60 mL/min/1.73 m as such, had full access to all the data in this work and will take responsibility for the integrity of the data and the accuracy of the data analysis.
